A Single Ascending Dose, Single-Centre Study, to Assess Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation in Healthy Participants

2023-508810-41-00 Protocol TMC207TBC1006 Human pharmacology (Phase I) - Other Ended

Start 1 Jul 2024 · End 27 Apr 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol TMC207TBC1006

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 32
Countries 1
Sites 1

Tuberculosis

Key facts

Sponsor
Janssen Cilag International
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01]
Trial duration
1 Jul 2024 → 27 Apr 2026
Decision date (initial)
2024-06-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Tuberculosis

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Austria Ended 32 1
Rest of world 0

Investigational sites

Austria

1 site · Ended
Medical University Of Vienna
clinical pharmacology, Waehringer Guertel 18-20, Alsergrund, Vienna

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Austria 2024-07-01 2026-04-27 2024-07-02 2025-05-01

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-27 Austria Acceptable
2024-06-17
2024-06-24
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-20 Austria Acceptable 2024-10-07
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-11-25 Austria Acceptable 2024-11-25
4 NON SUBSTANTIAL MODIFICATION NSM-2 2025-02-20 Austria Acceptable 2025-02-20
5 NON SUBSTANTIAL MODIFICATION NSM-3 2025-02-24 Austria Acceptable 2025-02-24
6 NON SUBSTANTIAL MODIFICATION NSM-4 2025-04-24 Austria Acceptable 2025-04-24
7 SUBSTANTIAL MODIFICATION SM-2 2025-05-26 Austria Acceptable 2025-07-07